Retatrutide 10mg

Description

Retatrutide 10 mg is a synthetic triple-agonist peptide under investigation in metabolic research. Designed to engage GIP, GLP-1, and glucagon receptors simultaneously, it has been studied in preclinical models of energy expenditure, glucose handling, and body-composition research.

Research Profile

• Triple-agonist activity across GIP, GLP-1, and glucagon receptors
• Studied in metabolic and energy-balance research models
• Lyophilized format for stable, long-term storage
• QC verified by HPLC and mass spectrometry

Specifications

• Compound: Retatrutide (LY3437943)
• Dosage: 10 mg per vial
• Purity: ≥ 98% (HPLC)
• Form: Lyophilized powder
• Storage: 2–8 °C (lyophilized); –20 °C (reconstituted)

For research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.